

## ESPS JOURNAL EDITOR-IN-CHIEF'S REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pathophysiology

**ESPS manuscript NO:** 20796

**Title:** Promising biological therapies for ulcerative colitis: A review of the literature

**Journal Editor-in-Chief (Associate Editor):** Thomas Y Ma

**Country:** United States

**Editorial Director:** Xiu-Xia Song

**Date sent for review:** 2015-10-14 17:28

**Date reviewed:** 2015-10-17 05:59

ACADEMIC CONTENT EVALUATION	LANGUAGE QUALITY EVALUATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input checked="" type="checkbox"/> Revision
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		

### JOURNAL EDITOR-IN-CHIEF (ASSOCIATE EDITOR) COMMENTS TO AUTHORS

In this review manuscript, the authors review the use of biologics in the treatment of UC. It is well-written and covers the recently approved biologics for UC. There is an important flaw in the review that must be corrected. Although the authors mention various studies with different biologics, they omit or overlook a critical component of the studies. They do not discuss the outcome of the studies presented. This is a critical flaw and must be corrected before the manuscript can be considered for publication. The authors need to state the outcome of the studies mentioned with regards to infliximab, adalimumab, golimumab, etc....